pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Hepatology · news · pharmadog
← back to Hepatology
News · Hepatology
262
stories
2d
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
2d
FDA pushes decision on Belite’s eye disease pill back to May
fiercebiotech
3d
Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
biospace
3d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
3d
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
biospace
3d
nChroma halves headcount, calls time on trial of potential HBV ‘cure’
fiercebiotech
4d
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
4d
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
biospace
9d
Opinion: New organ donation rules are unfair to families
stat
9d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
9d
Game Changer Products LLC Issues Voluntary Nationwide Recall of 10 Day Forecast Capsules Due to the Presence of Undeclared Sildenafil and Acetaminophen
fda recalls
12d
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
biospace
12d
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
biospace
12d
FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
fda press
12d
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
biospace
12d
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
biospace
12d
Vir hepatitis D drug succeeds in first pivotal study
biopharma dive
13d
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
fiercebiotech
13d
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
stat
13d
Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
biospace
13d
AI chatbots aren’t therapists. But can they finally get men to open up?
stat
13d
Liver experts finally agree on what acute-on-chronic liver failure is
stat
13d
Vir’s phase 3 hepatitis delta win fuels push to eclipse Gilead
fiercebiotech
15d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
15d
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
biopharma dive
16d
Agios axes 100-plus R&D roles while awaiting FDA decision
biospace
16d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
16d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
17d
#AASLD26: Merck unwraps biopsy data for MASH drug it got from South Korea's Hanmi
endpoints
17d
MetaVia sees GLP-1 shed liver fat and body weight in phase 1, takes aim at specific liver disease
fiercebiotech
← prev
page 1 of 9
next →